Journal of intensive care medicine · 2025
The Role of Methylene Blue and Cyanocobalamin for Vasoplegic Syndrome in Liver Transplantation.
СтатьяСистематический обзорКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Longhitano Yaroslava, Albuelkasem Ezeldeen, Voza Antonio, La Via Luigi, Zanza Christian, Planinsic Raymond M
Аннотация
Vasoplegic syndrome is a complication that may occur during liver transplantation, most often after donor graft reperfusion. Multiple factors in end-stage liver disease (ESLD) may contribute to this vasodilation which may be exacerbated during reperfusion in liver transplantation. Two cases of vasoplegia during living donor liver transplantation are reported along with a systematic review of current literature. These patients were successfully treated with methylene blue and cyanocobalamin. All publications between January 1992 to september 2024 that assessed the use of methylene blue and/or cyanocobalamin in vasoplegia during liver transplantation in humans were included. Seven case reports and one case series were found and reviewed. These consisted of 4 case reports of vasoplegic syndrome during liver transplantation treated with methylene blue and other four describing the use of cyanocobalamin. A total of twenty-four patients were treated with methylene blue and eight patients with cyanocobalamin in the reviewed articles and all patients had a beneficial impact on blood pressure after administration of the medications. Patients affected by vasoplegia during liver transplantation show encouraging results when treated with methylene blue and cyanocobalamin, but these data have to be confirmed by additional studies.